The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene therapy (CGT) pipeline is dedicated to rare conditions.

Key market drivers we are seeing this year

• Surge in approvals for RNA-targeted drugs, ultra-rare treatments, and gene therapies.
• The FDA is leaning into rare disease via the Rare Disease Innovation Hub and ARC program, but flexibility on pathways is being met with stricter manufacturing and evidence expectations.
• Large pharma is moving away from early-stage speculation, focusing instead on de-risked assets and scalable platforms.

2026 Policy Milestones: A New Regulatory Framework

The policy environment in 2026 is defined by a commitment to early detection balanced against intense pricing pressure.

A landmark moment occurred on February 3, 2026, with the signing of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act. This established a clear Medicare coverage pathway for FDA-approved multi-cancer blood-based diagnostics. For rare disease developers, this signals a national commitment to precision diagnostics that will ultimately accelerate the path from diagnostics to treatment.

When it comes to global and US pricing dynamics, innovators must now navigate a complex web of informal guardrails and formal policies:

• Ongoing US pricing negotiations, related to the Inflation Reduction Act (IRA), are reshaping the lifecycle of orphan assets.
• Because of CMMI demonstrations, new models like CGTAM, GENEROUS, GUARD, and GLOBE are testing how the system handles high-cost, low-volume therapies.
• Most-Favored Nation (MFN) logic and global budget pressures are forcing a defensive posture on premium pricing.

Pressure-Testing Your Access Strategy: 6 Critical Questions

To succeed in 2026, rare disease teams must evaluate their launch readiness through the lens of a payer. If you cannot answer these questions, your value story may not hold up to scrutiny:

1. Is our data package, often involving small populations or single-arm trials, robust enough for HTA bodies to trust?
2. How are we tracking long-term outcomes and comparative effectiveness after the initial launch?
3. Are we effectively using patient experience and caregiver burden data as actionable evidence for decision-makers?
4. How will ex-US launch sequences and confidential discounts impact our US and global price expectations?
5. Can we demonstrate that our strategy mitigates site-of-care barriers and supports underserved populations?
6. Have we embedded HEOR and RWE early enough in development to survive the initial signal of budget impact?

How ADVI Health Navigates Complexity

At ADVI Health, we help innovators connect the dots between scientific breakthroughs and sustainable patient access. We provide a comprehensive suite of services designed for the 2026 environment:

• We scenario-plan around IRA, 340B, and CMMI demonstrations to ensure your asset is protected throughout its lifecycle.
• Our proprietary SAVES platform embeds HEOR and access strategy upstream. It allows clients to link epidemiology and policy context into analytically defensible budget narratives, helping to translate clinical uncertainty into manageable access conditions.
• We design outcomes-based and milestone-based models that address payer concerns regarding durability and financial toxicity.
• We bring a payer perspective to business development, helping you understand how asset structures will affect long-term strategic flexibility.

Get in touch to learn how we can help you pressure-test your evidence and pricing strategy.

---

Marc Samuels, JD, MPH
Chief Executive Officer

Caitlin Sheetz, MPH
Senior Vice President and Head of Strategic Analytics, Value and Economics